Solar Urticaria: Causes, Symptoms, Diagnosis and Treatment

What is Solar Urticaria?

Solar urticaria is a rare, acquired, chronic photosensitivity disorder. To fully understand this condition, it helps to break down each element of its definition:

• Urticaria: The name comes from the observation that the skin reaction closely resembles the rash caused by contact with stinging nettles (Urtica dioica). This reaction is characterized by raised, itchy wheals.
• Chronic: The condition persists over a prolonged period of time, often for years.
• Photosensitivity: Triggered by exposure to sunlight or ultraviolet (UV) radiation more generally.
• Acquired: The condition develops after birth in response to environmental or immunological factors, rather than being congenital.

Solar urticaria involves recurrent episodes of urticaria, which are itchy, raised skin reactions that affect areas exposed to sunlight. Although it is generally considered a benign condition from a strictly medical standpoint, it can be profoundly disabling: patients may be forced to avoid outdoor activities, sunlight exposure, and even brightly lit indoor environments, leading to a severe deterioration in quality of life, mood, and social functioning.

---

Causes

The skin reaction in solar urticaria is directly triggered by exposure to sunlight. However, the precise spectrum of light responsible varies considerably from patient to patient. Some react to UVA rays, others to UVB rays, and some even to visible light wavelengths.

Epidemiology

Solar urticaria is a rare condition, accounting for:

• Fewer than 1% of all urticaria cases
• Fewer than 10% of all photodermatoses (the broader group of sun-related skin reactions)

The disease typically presents in young to middle-aged adults, with a reported median age of onset of approximately 35 years, though cases in children and older adults have been described. The literature reports a slight female predominance. A personal or family history of atopic disease (atopic dermatitis, asthma, allergic rhinitis) represents a significant risk factor.

Pathophysiology

The precise biochemical mechanisms underlying solar urticaria remain incompletely understood. The current leading hypothesis describes it as a hypersensitivity reaction, potentially IgE-mediated. Immunoglobulin E, or IgE, is a class of antibodies typically involved in allergic responses.

The prevailing theory suggests that solar radiation transforms an endogenous molecule, a substance naturally present in the skin, into a photoallergen. This photoallergen is a structurally altered molecule that can activate mast cells, triggering an immune response. As a result, histamine and other inflammatory mediators are released.

Supporting this hypothesis is the observation that solar urticaria can occasionally be provoked by exogenous (external) photosensitizing substances, including certain medications such as:

• Atorvastatin (a cholesterol-lowering statin)
• Chlorpromazine (an antipsychotic)
• Tetracyclines (broad-spectrum antibiotics)
• Oral contraceptives (you can also read our article on the contraceptive pill for more details)

When a drug-induced cause is identified, the condition may resolve upon discontinuation of the offending agent.

---

Symptoms

Onset and Distribution

The hallmark of solar urticaria is the rapid onset of skin lesions. These usually appear within minutes of sun exposure, specifically on areas directly exposed to sunlight. Importantly, lesions can also develop under thin or white clothing, which does not provide full UV protection.

Areas most commonly affected include:

• Forearms, upper arms, shoulders, and décolletage
• Upper back and lower legs
• Any sun-exposed body part

Hands and the face are often relatively spared, possibly because chronic low-level sun exposure in these areas leads to a degree of acquired tolerance. However, some patients develop periorbital angioedema (swelling around the eyes), which can be alarming.

Skin Manifestations

The typical cutaneous reaction includes:

• Edematous papules: raised lesions less than 1 cm in diameter that are perceptible to the touch.
• Wheals (pomfi): larger, irregular raised areas.
• Erythema (redness): diffuse or localized skin flushing.
• Burning sensation and intense itching (pruritus).

In 75% of cases, skin symptoms resolve within one hour of stopping sun exposure. However, both the severity and duration of symptoms are directly proportional to the intensity and duration of light exposure.

Systemic Symptoms

When large areas of skin are involved, systemic symptoms may occur because histamine is released and fluid is redistributed toward the skin. Here are the key signs to watch for:

• Nausea and vomiting
• Wheezing
• Bronchospasm and shortness of breath (dyspnea)
• Dizziness or fainting (syncope)
• Headache and malaise

In rare but serious cases, anaphylactic shock has been reported. This condition is a potentially life-threatening reaction that involves airway compromise and cardiovascular collapse. This represents a medical emergency requiring immediate intervention.

---

Complications

Medical Complications

Although serious medical complications are rare, they are clinically important:

• Anaphylactic shock: Documented in isolated cases, particularly following intense, widespread sun exposure. Patients at risk should carry an epinephrine auto-injector (EpiPen) and wear a medical alert bracelet.
• Angioedema: Deep tissue swelling, most frequently periorbital (around the eyes), can occur independently of or alongside typical urticarial wheals.

Impact on Quality of Life

The most frequent and impactful complication is not strictly medical but psychosocial. Solar urticaria is predominantly a chronic condition that remits spontaneously in only a subset of patients. The inability to be exposed to sunlight, even through glass or under some types of artificial lighting, creates severe restrictions.

• Outdoor activities (sports, gardening, leisure)
• Professional life (outdoor occupations, commuting)
• Social interactions (vacations, outdoor social gatherings)
• Emotional wellbeing: Depression and anxiety are significantly more prevalent in this patient population.

The psychological burden of solar urticaria is frequently underestimated by both patients and healthcare providers, and it should be proactively addressed as part of a comprehensive management plan.

---

Diagnosis

Clinical Suspicion

Diagnosis of solar urticaria is initially suspected on clinical grounds, during the dermatologist’s detailed interview (anamnesis) about the nature, timing, and distribution of skin lesions in relation to sun exposure. A characteristic history, such as the rapid onset of itchy wheals on sun-exposed areas that resolve within an hour of seeking shade, is highly suggestive.

Differential Diagnosis

Solar urticaria must be distinguished from other photosensitivity disorders and sun-related skin conditions:

Phototesting (Light Testing)

The definitive diagnostic tool for solar urticaria is phototesting, performed by a dermatologist or photobiologist in a controlled clinical setting. Standardized light sources emitting UVA, UVB, and visible light are applied to small areas of skin (typically the lower back or forearm) in increasing doses.

Phototesting serves two critical purposes:

1. Confirmation of diagnosis: A reproducible urticarial response to a specific wavelength confirms solar urticaria.
2. Characterization of the action spectrum: Identifying the precise wavelengths that trigger the reaction guides both sun avoidance strategies and treatment choices, such as selecting appropriate sunscreen filters.
3. Determination of the minimal urticarial dose (MUD) refers to identifying the smallest amount of light exposure required to trigger a reaction. This measurement has direct practical implications for daily management.

Photopatch Testing

A photopatch test may be performed to exclude drug-induced photosensitivity or photocontact dermatitis, where the reaction is triggered by a combination of a substance applied to the skin and UV exposure.

Additional Laboratory Workup

In selected patients, the clinician may request:

• Serum IgE levels and specific IgE testing
• Antinuclear antibodies (ANA) and complement levels to exclude lupus
• Complete blood count and inflammatory markers to assess general health status
• Porphyrin levels to rule out erythropoietic protoporphyria

---

Treatment

While diagnosis of solar urticaria is relatively straightforward in experienced hands, its management presents considerably greater challenges. Treatment must be individualized based on the severity of the condition, the patient’s action spectrum, and their response to initial therapies.

Sun Avoidance and Physical Protection

The most fundamental management strategy is minimizing sun exposure, particularly during peak UV hours (10 a.m. to 4 p.m.). Practical measures include:

• Broad-spectrum sunscreens should be applied daily to all exposed areas. The SPF and UV filter choice should be guided by the patient’s specific action spectrum, as determined by phototesting.
• Sun-protective clothing: Dark, tightly woven fabrics provide significantly better UV shielding than light or white garments.
• UV-blocking window films for cars and home windows, as some patients react to light transmitted through standard glass.
• Seeking shade and using UV-protective accessories (hats, UV-blocking sunglasses).

First-Line Pharmacotherapy: Antihistamines

The first-line pharmacological treatment consists of H1 antihistamines, as in virtually all forms of allergic and urticarial reactions. Commonly used agents include:

• Fexofenadine is non-sedating, effective, and well tolerated for long-term use.
• Loratadine / Desloratadine: non-sedating second-generation agents.
• Cetirizine / Levocetirizine: These medications are highly effective, though some patients may experience mild drowsiness.
• Diphenhydramine is a first-generation antihistamine. It is useful for acute breakthrough reactions but not suitable for long-term daily use because it causes sedation.

As per international guidelines, up-dosing antihistamines (up to 4 times the standard daily dose) under medical supervision is recommended before escalating to other therapies.

Desensitization (Phototherapy)

Since chronically exposed areas of skin appear to develop a degree of acquired tolerance to sunlight in some patients, controlled light exposure, also known as desensitization or hardening therapy, has been used with varying success.

• PUVA therapy (Psoralen + UVA): The patient takes a photosensitizing drug (psoralen) followed by controlled UVA exposure in a clinical setting; this induces tolerance to UV radiation. It is one of the most effective desensitization approaches.
• Narrowband UVB phototherapy: A safer alternative to PUVA, particularly useful in patients whose action spectrum includes UVB.
• Natural sunlight desensitization: Gradual, controlled self-exposure beginning in early spring (when UV intensity is still relatively low) can help some patients build tolerance before the summer months. This must be approached cautiously and under medical guidance.

The effects of desensitization are unfortunately temporary, typically lasting only days to a few weeks without ongoing maintenance exposure.

Second-Line and Advanced Therapies

For patients with severe, antihistamine-resistant solar urticaria, more advanced treatment options are available:

• Omalizumab (anti-IgE monoclonal antibody): Increasingly recognized as a highly effective option in solar urticaria, particularly given the likely IgE-mediated pathogenesis. Administered as a subcutaneous injection every 4 weeks, it has demonstrated rapid and sustained symptom improvement in published case series and small clinical trials.
• Plasmapheresis (plasma exchange): Based on the rationale of removing the circulating photoallergen or IgE antibodies responsible for the reaction. Reserved for severe, refractory cases; effects are temporary.
• Intravenous immunoglobulins (IVIG): Used in exceptional cases unresponsive to all other therapies.
• Cyclosporine and other immunosuppressants: May be considered in severe, refractory cases, with appropriate monitoring.

Treatments of Limited or No Proven Efficacy

The following agents have been investigated but have not demonstrated reliable clinical benefit in solar urticaria and are therefore generally not recommended:

• Systemic corticosteroids (cortisone) show no evidence of sustained efficacy in solar urticaria
• Leukotriene receptor antagonists (e.g., montelukast)
• Antimalarial drugs (e.g., hydroxychloroquine)
• Prostaglandin inhibitors
• Beta-carotene (oral)

Emergency Preparedness

Patients at risk of severe systemic reactions or anaphylaxis should:

• Always carry a prescription epinephrine auto-injector (EpiPen)
• Wear a medical alert bracelet indicating their diagnosis
• Receive training on recognizing and responding to early signs of anaphylaxis
• Develop an individualized emergency action plan in collaboration with their dermatologist and/or allergist

---

Sources and Bibliography

• Solar Urticaria: Blair W. Harris; Talel Badri; Joel Schlessinger. StatPearls, NCBI Bookshelf.
• Zuberbier T, et al. The EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766.
• Magerl M, et al. The definition and diagnostic testing of physical and cholinergic urticarias: EAACI/GA²LEN/EDF/UNEV consensus panel recommendations. Allergy. 2009;64(12):1715–1721.
• Borzova E, Grattan C. Solar urticaria. Photodermatology, Photoimmunology & Photomedicine. 2010;26(3):118–127.
• Horio T. Solar urticaria: photoallergen in serum. Archives of Dermatology. 1978;114(11):1611–1613.